Physician profile
Daniel E Montero
NPI 1376591842
$13,932.69
in general payments reported to CMS, 2019-2025
55 companies · $1,783 in 2025
The $1,783 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,501 · 2020: $2,230 · 2021: $3,035 · 2022: $1,943 · 2023: $1,060 · 2024: $1,381 · 2025: $1,783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,210 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,210.21 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,263.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $2,054.50 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Sanofi-Aventis U.S. LLC | $992.44 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $832.18 | 2020-2025 | Jardiance |
| Lilly USA, LLC | $679.05 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Corcept Therapeutics | $650.48 | 2021-2025 | Korlym |
| Amgen INC. | $589.05 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $555.30 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $529.10 | 2021-2025 | |
| Dexcom, INC. | $506.53 | 2019-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $372.20 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Abbvie INC. | $329.18 | 2021-2024 | |
| Mannkind Corporation | $317.85 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $294.81 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $252.72 | 2021-2025 | Gvoke Hypopen |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Montero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.